Setback for Novartis Hepatitis Drug
April 20, 2012
On Thursday, the Food and Drug Administration placed the development of an experimental hepatitis C drug on hold after the death of a patient that could be linked to it.
Switzerland-based Novartis AG is developing the drug, known as DEB025 or alisporivir. Rather than targeting hepatitis C virus directly, as other treatments do, it focuses on proteins that are essential for viral replication. Novartis proceeded with late-stage testing after intermediate studies last year showed alisporivir was effective in eliminating HCV.
Novartis said a small number of patients who received DEB025, in addition to pegylated interferon and ribavirin, developed pancreatitis, which is thought to be a contributing factor in the patient's death. This was the only death in the DEB025 program, which has involved about 1,800 patients to date, Novartis said.
David Kaegi, an analyst with Zurich's Bank Sarasin, said the drug's role in the death "remains to be determined. The case is open."
Wall Street Journal
04.19.2012; Marta Falconi
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)